We hosted a dinner on PARP Inhibitors recently. PARP Inhibitors are a class of medications that may have benefits in Triple Negative and other Breast Cancers in women with a BRCA mutation. Homologous Recombination Deficiencies are associated with several cancers, including breast cancer, and can be identified in breast cancer tissue itself. Tumors with a homologous recombination deficiency (including BRCA mutations) are described as HRD-positive.

Read more on More Hope For PARP Inhibitors In Treating Breast Cancer…